16th Apr 2024 14:11
The following amendment has been made to the 'Director/PDMR Shareholding' announcement released on 15 April 2024 at 15:30 under RNS No 6703K:
- A typographical correction to the share price for the transaction shown in the table below.
All other details to the original announcement remain unchanged.
The amended table is shown below.
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | David Redfern | |||
b) | Position/status | Chief Strategy Officer | |||
c) | Initial notification/ amendment | Amendment | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63 | |||
b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2024, on Ordinary Shares held within an ISA
| |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£16.3860 | 19 | ||||
d) | Aggregated information
| N/A (single transaction)
| |||
Aggregated volume Price | |||||
e) | Date of the transaction | 2024-04-12 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
Related Shares:
Glaxosmithkline